1 Dividend Stock to Buy Hand Over Fist and 1 to Avoid

Core Insights - Demand for GLP-1 drugs is expected to remain strong, significantly boosting Eli Lilly's growth and stock price, but there may be better investment opportunities in the pharmaceutical sector [1][2] Group 1: Eli Lilly - Eli Lilly's GLP-1 drugs, Mounjaro and Zepbound, are leading the market with projected revenue growth of 99% and 175% respectively by 2025, contributing to 56% of the company's total revenue [2] - The stock price of Eli Lilly has surged, resulting in a high price-to-earnings (P/E) ratio of 44 and a low dividend yield of 0.6%, indicating that the stock is priced for perfection [3] - Despite its strong business performance, Eli Lilly is considered expensive compared to its peers, making it less attractive for value-focused investors [7] Group 2: Merck - Merck operates in different therapeutic areas such as cancer, infections, and cardiometabolic diseases, which are crucial despite being less trendy than weight loss treatments [4] - Merck's P/E ratio is significantly lower at 16, and it offers a higher dividend yield of 2.8%, making it a more appealing option for income-focused investors [6] - The company has a robust pipeline of new drugs and international patents for Keytruda that extend into the early 2030s, mitigating concerns over upcoming patent expirations [5][6]